- Home
- BENF vs MGNX Comparison
BENF vs MGNX Comparison
Compare BENF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BENF
- MGNX
- Stock Information
- Founded
- BENF 2003
- MGNX 2000
- Country
- BENF United States
- MGNX United States
- Employees
- BENF N/A
- MGNX N/A
- Industry
- BENF Blank Checks
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- BENF Finance
- MGNX Health Care
- Exchange
- BENF Nasdaq
- MGNX Nasdaq
- Market Cap
- BENF 91.9M
- MGNX 99.7M
- IPO Year
- BENF N/A
- MGNX 2013
- Fundamental
- Price
- BENF $0.51
- MGNX $1.36
- Analyst Decision
- BENF
- MGNX Hold
- Analyst Count
- BENF 0
- MGNX 6
- Target Price
- BENF N/A
- MGNX $3.20
- AVG Volume (30 Days)
- BENF 27.8M
- MGNX 824.5K
- Earning Date
- BENF 11-14-2025
- MGNX 11-04-2025
- Dividend Yield
- BENF N/A
- MGNX N/A
- EPS Growth
- BENF N/A
- MGNX N/A
- EPS
- BENF N/A
- MGNX N/A
- Revenue
- BENF N/A
- MGNX $165,495,000.00
- Revenue This Year
- BENF N/A
- MGNX N/A
- Revenue Next Year
- BENF $22.09
- MGNX N/A
- P/E Ratio
- BENF N/A
- MGNX N/A
- Revenue Growth
- BENF N/A
- MGNX 303.47
- 52 Week Low
- BENF $0.22
- MGNX $0.99
- 52 Week High
- BENF $2.36
- MGNX $4.87
- Technical
- Relative Strength Index (RSI)
- BENF 45.46
- MGNX 33.29
- Support Level
- BENF $0.54
- MGNX $1.82
- Resistance Level
- BENF $0.93
- MGNX $1.69
- Average True Range (ATR)
- BENF 0.17
- MGNX 0.14
- MACD
- BENF -0.04
- MGNX -0.05
- Stochastic Oscillator
- BENF 5.39
- MGNX 5.85
About BENF Beneficient
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.